COVID-19 Lockdowns Caused Major Delays in Melanoma Diagnoses, Costing Billions
Delays in diagnosing melanoma due to COVID-19 lockdown may have contributed to more than 100,000 years of life lost across Europe and over £6 billion mainly indirectly due to loss of productivity, according to new research in JAMA Network Open. For the study, a team of researchers from the UK, Switzerland, Germany, US, Italy, Australia and Hungary, looked at […]
Scabies Toolbox Part 2: Newly Improved Treatments for Parasitic Skin Infections
Ted Rosen, MD, discusses diagnosis of and currently recommended and alternative treatment regimens for scabies, including existing unmet treatment needs. Angela D. Pierce, NP, and Douglas DiRuggiero, DMSc, MHs, PA-C, offer specific commentary for NPs and PAs. About This Educational Video Series This is the second video in a scabies educational series designed for NPs and PAs. […]
Scabies Toolbox Part 1: Incidence and Prevalence
Scabies is a nondiscriminatory, widespread disease that affects about 3% of the world population at any given time. In Part 1 of this educational video series, Ted Rosen, MD, discusses the incidence and prevalence of scabies, emphasizing the importance of timely treatment. Angela D. Pierce, NP, and Douglas DiRuggiero, DMSc, MHs, PA-C, offer specific commentary for NPs […]
Part 3. An Innovative Scabies Treatment
In Part 3 of this educational video series, Dr. Christopher Belcher discusses the safety and efficacy of Natroba (Spinosad) 0.9% topical FDA-approved for the treatment of head lice and scabies. About This Series In this 3-part educational series, Drs. Ted Rosen and Christopher Belcher discuss the treatment landscape for scabies, with an examination of current […]
Part 2. Current Scabies Treatment Paradigms
In Part 2 of this educational video series, Dr. Ted Rosen discusses the diagnosis of and recommended and alternative treatment regimens for scabies, including existing unmet treatment needs. Scabies is a nondiscriminatory, widespread disease that affects about 3% of the world population at any given time. Current treatment regimens include permethrin 5% cream, oral ivermectin […]
Terbinafine resistance: A rising and worrisome specter
Steven Hainsworth, BAppSci, MMedSc, with Cheryl Guttman Krader For almost three decades, the allylamine antifungal drug terbinafine has been the first-line drug for treating dermatophyte infections, and it remains a reliable choice. However, dermatologists should be aware that terbinafine resistance is a real phenomenon that appears to be on the rise and spreading, said Steven […]